Brief: Terns Pharmaceuticals Q3 Net Income USD -21.945 Million Vs. IBES Estimate USD -25.7 Million
12/11/2024 21:05
Nov 12 (Reuters) - Terns Pharmaceuticals Q3 operating expenses USD 24.939 million. * Q3 basic EPS USD -0.28 * Q3 income from operations USD -24.939 million vs. IBES estimate USD -27.3 million * Q3 pretax profit USD -21.883 million vs. IBES estimate USD -25.7 million
Recent news on Terns Pharmaceuticals
See all newsNASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
U.S. RESEARCH ROUNDUP-East West Bancorp, Reliance, S&P Global
Brief: Merck Announces Expiration Of Hart-Scott-Rodino Act Waiting Period To Acquire Terns Pharmaceuticals
Brief: Merck Begins Tender Offer To Acquire Terns Pharmaceuticals, Inc.